prospective longitudinal assessment of cardiovascular toxicity of childhood cancer treatment

Completed

• Conditions: 10047066; cardiac dysfunction; decreased heartfunction; 10082206

• Registration Number: NL-OMON32995
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 225

Inclusion Criteria

newly diagnosed childhood cancer patients
age 0-18 years
written informed consent

Exclusion Criteria

inadequate knowledge of the dutch language for reading the information and writing informed consent

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1. Prevalence of subclinical cardiac damage (diagnosed by echocardiography as<br /><br>either systolic, diastolic or combined<br /><br>dysfunction)<br /><br><br /><br>2. Prevalence of cardiovascular risk factors (blood pressure, vascular wall<br /><br>changes, body composition and<br /><br>metabolic syndrome)<br /><br><br /><br>3. Changes in intima media thickness in carotid-/femoral arteries after<br /><br>treatment with anthracyclines and/or<br /><br>thoracal/neckradiation.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>NA</p><br>